Ankit Mehta, MD
Nephrology · Dallas, TXNPI 1295944346
Payments from drug & device makers
Across 1,608 payments — averaging $1896.60 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Chiesi USA, Inc.$777K
- Sanofi$665K
- AstraZeneca$415K
- Novartis$307K
- Amgen$227K
- Akebia Therapeutics Inc$181K
- plus $478K from 27 others
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Chiesi USA, Inc. | 267 | $776,507 |
| Sanofi | 395 | $665,171 |
| AstraZeneca | 512 | $415,274 |
| Novartis | 9 | $307,036 |
| Amgen(2 entities) | 44 | $227,078 |
| Akebia Therapeutics Inc | 73 | $180,914 |
| Bayer | 131 | $145,019 |
| Sanofi US Services Inc. | 6 | $94,289 |
| Bristol Myers Squibb | 1 | $75,459 |
| Johnson & Johnson | 56 | $48,455 |
| Biogen | 1 | $35,750 |
| Amicus Therapeutics, Inc. | 5 | $22,750 |
| Pharmacosmos Therapeutics Inc. | 20 | $20,740 |
| GSK | 10 | $13,067 |
| Novo Nordisk AS | 47 | $8,559 |
| Travere Therapeutics, Inc. | 9 | $4,103 |
| Exthera Medical Corporation | 1 | $3,250 |
| Lilly USA, LLC | 1 | $2,400 |
| Alnylam Pharmaceuticals Inc. | 2 | $1,647 |
| E.r. Squibb & Sons, L.L.C. | 1 | $753 |
| Vertex | 1 | $516 |
| Aurinia Pharma U.S., Inc. | 2 | $218 |
| Fresenius USA Marketing, Inc. | 3 | $193 |
| Stryker | 1 | $163 |
| Depuy Synthes Products, Inc. | 1 | $157 |
| Novo Nordisk | 1 | $105 |
| Boston Scientific | 2 | $51 |
| Otsuka America Pharmaceutical, Inc. | 1 | $26 |
| La Jolla Pharmaceutical Company | 1 | $24 |
| OPKO Pharmaceuticals, LLC | 1 | $18 |
| Genentech USA, Inc. | 1 | $17 |
| Nxstage Medical, Inc. | 1 | $16 |
| Ultragenyx Pharmaceutical Inc. | 1 | $14 |
How this compares
$3,049,736 in reported general payments places this provider in the 95th percentile of 1,070 nephrology providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other nephrology in Dallas
- Irfan AghaDallas$3M
- David WojciechowskiDallas$1.6M
- Biff PalmerDallas$867K
- Gates ColbertDallas$828K
- Mark LermanDallas$564K
- Sumit KumarDallas$561K
- Robert TotoDallas$442K
- Akinwande AkinfolarinDallas$423K
- Deepa AmberkerDallas$300K
- Pablo PergolaSan Antonio$14.2M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.